Daesung Microbiological Labs. Co. Ltd (036480) - Net Assets
Based on the latest financial reports, Daesung Microbiological Labs. Co. Ltd (036480) has net assets worth ₩35.22 Billion KRW (≈ $23.87 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩57.87 Billion ≈ $39.22 Million USD) and total liabilities (₩22.65 Billion ≈ $15.35 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Daesung Microbiological Labs. Co. Ltd to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩35.22 Billion |
| % of Total Assets | 60.86% |
| Annual Growth Rate | 4.93% |
| 5-Year Change | -3.2% |
| 10-Year Change | 40.07% |
| Growth Volatility | 6.81 |
Daesung Microbiological Labs. Co. Ltd - Net Assets Trend (2012–2024)
This chart illustrates how Daesung Microbiological Labs. Co. Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Daesung Microbiological Labs. Co. Ltd balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for Daesung Microbiological Labs. Co. Ltd (2012–2024)
The table below shows the annual net assets of Daesung Microbiological Labs. Co. Ltd from 2012 to 2024. For live valuation and market cap data, see market cap of Daesung Microbiological Labs. Co. Ltd.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩35.15 Billion ≈ $23.82 Million |
-5.89% |
| 2023-12-31 | ₩37.35 Billion ≈ $25.31 Million |
-3.83% |
| 2022-12-31 | ₩38.84 Billion ≈ $26.32 Million |
+4.96% |
| 2021-12-31 | ₩37.00 Billion ≈ $25.08 Million |
+1.91% |
| 2020-12-31 | ₩36.31 Billion ≈ $24.61 Million |
+3.48% |
| 2019-12-31 | ₩35.09 Billion ≈ $23.78 Million |
+6.31% |
| 2018-12-31 | ₩33.01 Billion ≈ $22.37 Million |
+8.95% |
| 2017-12-31 | ₩30.30 Billion ≈ $20.53 Million |
+4.43% |
| 2016-12-31 | ₩29.01 Billion ≈ $19.66 Million |
+15.61% |
| 2015-12-31 | ₩25.09 Billion ≈ $17.01 Million |
+18.71% |
| 2014-12-31 | ₩21.14 Billion ≈ $14.32 Million |
+7.21% |
| 2013-12-31 | ₩19.72 Billion ≈ $13.36 Million |
-0.08% |
| 2012-12-31 | ₩19.73 Billion ≈ $13.37 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Daesung Microbiological Labs. Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 107.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩27.00 Billion | 76.83% |
| Common Stock | ₩1.90 Billion | 5.41% |
| Other Components | ₩6.24 Billion | 17.77% |
| Total Equity | ₩35.15 Billion | 100.00% |
Daesung Microbiological Labs. Co. Ltd Competitors by Market Cap
The table below lists competitors of Daesung Microbiological Labs. Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Mesiniaga Bhd
KLSE:5011
|
$18.96 Million |
|
Bharat Road Network Limited
NSE:BRNL
|
$18.96 Million |
|
Hubei Geoway Investment Co Ltd
SHG:600462
|
$18.96 Million |
|
Pasithea Therapeutics Corp
NASDAQ:KTTA
|
$18.96 Million |
|
DATRIX S.P.A.
F:BW6
|
$18.95 Million |
|
Aelis Farma SA
PA:AELIS
|
$18.95 Million |
|
Evoke Pharma Inc
NASDAQ:EVOK
|
$18.95 Million |
|
4Sight Holdings Ltd
JSE:4SI
|
$18.95 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Daesung Microbiological Labs. Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 37,348,624,940 to 35,149,367,370, a change of -2,199,257,570 (-5.9%).
- Net loss of 1,769,362,730 reduced equity.
- Dividend payments of 285,000,000 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-1.77 Billion | -5.03% |
| Dividends Paid | ₩285.00 Million | -0.81% |
| Other Changes | ₩-144.89 Million | -0.41% |
| Total Change | ₩- | -5.89% |
Book Value vs Market Value Analysis
This analysis compares Daesung Microbiological Labs. Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.80x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.96x to 0.80x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩7634.61 | ₩7360.00 | x |
| 2017-12-31 | ₩7972.76 | ₩7360.00 | x |
| 2018-12-31 | ₩8686.65 | ₩7360.00 | x |
| 2019-12-31 | ₩9234.52 | ₩7360.00 | x |
| 2020-12-31 | ₩9555.62 | ₩7360.00 | x |
| 2021-12-31 | ₩9737.79 | ₩7360.00 | x |
| 2022-12-31 | ₩10220.37 | ₩7360.00 | x |
| 2023-12-31 | ₩9828.59 | ₩7360.00 | x |
| 2024-12-31 | ₩9249.83 | ₩7360.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Daesung Microbiological Labs. Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -5.03%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -7.43%
- • Asset Turnover: 0.41x
- • Equity Multiplier: 1.66x
- Recent ROE (-5.03%) is below the historical average (6.38%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 9.66% | 8.07% | 0.91x | 1.31x | ₩-71.44 Million |
| 2015 | 18.13% | 14.67% | 0.96x | 1.29x | ₩2.04 Billion |
| 2016 | 15.49% | 14.59% | 0.87x | 1.23x | ₩1.59 Billion |
| 2017 | 5.14% | 6.48% | 0.69x | 1.15x | ₩-1.47 Billion |
| 2018 | 9.60% | 12.63% | 0.66x | 1.15x | ₩-130.80 Million |
| 2019 | 8.12% | 11.34% | 0.50x | 1.45x | ₩-659.14 Million |
| 2020 | 4.18% | 6.12% | 0.40x | 1.71x | ₩-2.11 Billion |
| 2021 | 2.34% | 3.61% | 0.38x | 1.69x | ₩-2.83 Billion |
| 2022 | 4.39% | 6.68% | 0.39x | 1.68x | ₩-2.18 Billion |
| 2023 | -1.82% | -2.66% | 0.40x | 1.72x | ₩-4.41 Billion |
| 2024 | -5.03% | -7.43% | 0.41x | 1.66x | ₩-5.28 Billion |
Industry Comparison
This section compares Daesung Microbiological Labs. Co. Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $445,388,943,687
- Average return on equity (ROE) among peers: 1.45%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Daesung Microbiological Labs. Co. Ltd (036480) | ₩35.22 Billion | 9.66% | 0.64x | $18.95 Million |
| ORIENTBIO Inc. (002630) | $62.65 Billion | -31.14% | 0.34x | $42.67 Million |
| Green Cross (005250) | $1.91 Trillion | 2.89% | 0.83x | $424.80 Million |
| Green Cross Holdings Preference Shares (005257) | $1.67 Trillion | 10.22% | 0.94x | $3.72 Million |
| Pharmicell (005690) | $76.66 Billion | 10.78% | 0.43x | $823.44 Million |
| GeneOne Life Science Inc (011000) | $33.79 Billion | 0.00% | 0.20x | $48.33 Million |
| HLB Co. Ltd (028300) | $21.19 Billion | 0.00% | 1.56x | $5.41 Billion |
| Seoulin Bioscience Co.Ltd (038070) | $59.71 Billion | 14.88% | 0.35x | $37.75 Million |
| Hyundai Bioscience Co. Ltd (048410) | $64.08 Billion | 0.00% | 2.13x | $937.21 Million |
| iNtRON Biotechnology Inc (048530) | $106.18 Billion | 5.38% | 0.33x | $74.45 Million |
About Daesung Microbiological Labs. Co. Ltd
Daesung Microbiological Labs. Co., Ltd. manufactures and sells vaccines for swine, poultry, canine, cattle, and fish in South Korea. It offers antibiotics and antibacterials, parasiticides and disinfectants, probiotics and enzyme products, and nutrients and pharmaceuticals. The company also exports its products. Daesung Microbiological Labs. Co., Ltd. was founded in 1966 and is headquartered in U… Read more